Targeting mTORC1-mediated metabolic addiction overcomes fludarabine resistance in malignant B cells

Molecular Cancer Research

Volumn 12, Issue 9, 2014, Pages 1205-1215

  Sharma, Arishya ^a,b   Janocha, Allison J ^a   Hill, Brian T ^c   Smith, Mitchell R ^c   Erzurum, Serpil C ^a   Almasan, Alexandru ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CLEVELAND STATE UNIVERSITY   (United States)

^c TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE CARBAMOYLTRANSFERASE; CARBAMOYL PHOSPHATE SYNTHASE (GLUTAMINE HYDROLYSING); DIHYDROOROTASE; EVEROLIMUS; FLUDARABINE; LEFLUNOMIDE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; RAPAMYCIN; SPARFOSIC ACID; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; PYRIMIDINE; PYRIMIDINE DERIVATIVE; RIBOSOMAL PROTEIN S6 KINASE, 70KD, POLYPEPTIDE 1; S6 KINASE; TARGET OF RAPAMYCIN KINASE; VIDARABINE;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GLYCOLYSIS; HUMAN; HUMAN CELL; LEUKEMIA CELL; MITOCHONDRIAL RESPIRATION; OXYGEN CONSUMPTION; PYRIMIDINE SYNTHESIS; RNA INTERFERENCE; ANALOGS AND DERIVATIVES; B LYMPHOCYTE; BIOSYNTHESIS; DRUG RESISTANCE; GENETICS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METABOLISM; OXIDATIVE PHOSPHORYLATION; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

B-LYMPHOCYTES; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GLYCOLYSIS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MULTIPROTEIN COMPLEXES; OXIDATIVE PHOSPHORYLATION; PYRIMIDINES; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; VIDARABINE;

EID: 84907273461     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-14-0124     Document Type: Article

References (45)

1. Gribben JG, O'Brien S. Update on therapy of chronic lymphocytic leukemia. J Clin Oncol 2011;29:544-50.
2. Hagenbeek A, Eghbali H, Monfardini S, Vitolo U, Hoskin PJ, de Wolf- Peeters C, et al. Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant Non-Hodgkin's lymphoma. J Clin Oncol 2006;24:1590-6.
3. Witzig TE, Gupta M. Signal transduction inhibitor therapy for lymphoma. Hematology Am Soc Hematol Educ Program 2010;2010: 265-70.
4. Fasolo A, Sessa C. Current and future directions in mammalian target of rapamycin inhibitors development. Expert Opin Investig Drugs 2011;20:381-94.
5. Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, Franklin RA, et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget 2011;2:135-64.
6. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012;149:274-93.
7. Menon S, Manning BD. Common corruption of the mTOR signaling network in human tumors. Oncogene 2008;27 Suppl 2:S43-51.
8. Strimpakos AS, Karapanagiotou EM, Saif MW, Syrigos KN. The role of mTOR in the management of solid tumors: an overview. Cancer Treat Rev 2009;35:148-59.
9. Dancey J. mTOR signaling and drug development in cancer. Nat Rev Clin Oncol 2010;7:209-19.
10. Chen X, Zhao M, Hao M, Sun X, Wang J, Mao Y, et al. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer. Mol Cancer Res 2013;11:1269-78.
11. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008; 14:1351-6.
12. Duvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, Souza AL, et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell 2010;39:171-83.
13. Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 2009;10:307-18.
14. Csibi A, Fendt SM, Li C, Poulogiannis G, Choo AY, Chapski DJ, et al. The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4. Cell 2013;153: 840-54.
15. Ben-Sahra I, Howell JJ, Asara JM, Manning BD. Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1. Science 2013;339:1323-8.
16. Robitaille AM, Christen S, Shimobayashi M, Cornu M, Fava LL, Moes S, et al. Quantitative phosphoproteomics reveal mTORC1 activates de novo pyrimidine synthesis. Science 2013;339:1320-3.
17. Howell JJ, Ricoult SJ, Ben-Sahra I, Manning BD. A growing role for mTOR in promoting anabolic metabolism. Biochem Soc Trans 2013; 41:906-12.
18. Parkhitko AA, Priolo C, Coloff JL, Yun J, Wu JJ, Mizumura K, et al. Autophagy-dependent metabolic reprogramming sensitizes TSC2- deficient cells to the antimetabolite 6-aminonicotinamide. Mol Cancer Res 2014;12:48-57.
19. Young RM, Ackerman D, Quinn ZL, Mancuso A, Gruber M, Liu L, et al. Dysregulated mTORC1 renders cells critically dependent on desaturated lipids for survival under tumor-like stress. Genes Dev 2013; 27:1115-31.
20. Neri LM, Cani A, Martelli AM, Simioni C, Junghanss C, Tabellini G, et al. Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential. Leukemia 2013; 28:739-48.
21. Sharma A, Singh K, Mazumder S, Hill BT, Kalaycio M, Almasan A. BECN1 and BIM interactions with MCL-1 determine fludarabine resistance in leukemic B cells. Cell Death Dis 2013;4:e628.
22. Cassano C, Mactier S, Mulligan SP, Belov L, Huang P, Christopherson RI. Cladribine and fludarabine nucleoside change the levels of CD antigens on B-lymphoproliferative disorders. Int J Proteomics 2010; 2010:964251.
23. Stacchini A, Aragno M, Vallario A, Alfarano A, Circosta P, Gottardi D, et al. MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation. Leuk Res 1999;23:127-36.
24. Al-Harbi S, Hill BT, Mazumder S, Singh K, Devecchio J, Choudhary G, et al. An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737. Blood 2011; 118:3579-90.
25. Ray S, Almasan A. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11. Cancer Res 2003;63:4713-23.
26. Gupta D, Crosby ME, Almasan A, Macklis RM. Regulation of CD20 expression by radiation-induced changes in intracellular redox status. Free Radic Biol Med 2008;44:614-23.
27. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
28. Davids MS, Brown JR. Targeting the Bcell receptor pathway in chronic lymphocytic leukemia. Leuk Lymphoma 2012;53:2362-70.
29. Li J, Kim SG, Blenis J. Rapamycin: one drug, many effects. Cell Metab 2014;19:373-9.
30. Dibble CC, Manning BD. Signal integration by mTORC1 coordinates nutrient input with biosynthetic output. Nat Cell Biol 2013;15:555-64.
31. Chen Q, Gong B, Almasan A. Distinct stages of cytochrome c release from mitochondria: evidence for a feedback amplification loop linking caspase activation to mitochondrial dysfunction in genotoxic stress induced apoptosis. Cell Death Differ 2000;7:227-33.
32. Hill BG, Benavides GA, Lancaster JR Jr., Ballinger S, Dell'Italia L, Jianhua Z, et al. Integration of cellular bioenergetics with mitochondrial quality control and autophagy. Biol Chem 2012;393:1485-512.
33. Beuneu C, Auger R, Loffler M, Guissani A, Lemaire G, Lepoivre M. Indirect inhibition of mitochondrial dihydroorotate dehydrogenase activity by nitric oxide. Free Radic Biol Med 2000;28:1206-13.
34. Paulson TG, Almasan A, Brody LL, Wahl GM. Gene amplification in a p53-deficient cell line requires cell cycle progression under conditions that generate DNA breakage. Mol Cell Biol 1998;18: 3089-100.
35. Evans DR, Guy HI. Mammalian pyrimidine biosynthesis: fresh insights into an ancient pathway. J Biol Chem 2004;279:33035-8.
36. Willems L, Tamburini J, Chapuis N, Lacombe C, Mayeux P, Bouscary D. PI3K andmTORsignaling pathways in cancer: new data on targeted therapies. Curr Oncol Rep 2012;14:129-38.
37. Wander SA, Hennessy BT, Slingerland JM. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest 2011;121:1231-41.
38. Velez J, Hail N Jr., Konopleva M, Zeng Z, Kojima K, Samudio I, et al. Mitochondrial uncoupling and the reprograming of intermediary metabolism in leukemia cells. Front Oncol 2013;3:67.
39. Locasale JW. Metabolic rewiring drives resistance to targeted cancer therapy. Mol Syst Biol 2012;8:597.
40. Komurov K, Tseng JT, Muller M, Seviour EG, Moss TJ, Yang L, et al. The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells. Mol Syst Biol 2012;8:596.
41. Dietrich S, Kramer OH, Hahn E, Schafer C, Giese T, Hess M, et al. Leflunomide induces apoptosis in fludarabine-resistant and clinically refractory CLL cells. Clin Cancer Res 2012;18:417-31.
42. Alers S, Loffler AS, Wesselborg S, Stork B. Role of AMPK-mTOR-Ulk1/ 2 in the regulation of autophagy: cross talk, shortcuts, and feedbacks. Mol Cell Biol 2012;32:2-11.
43. Guidarelli A, Clementi E, Brambilla L, Cantoni O. NADH-Linked substrate- mediated enhancement of mitochondrial calcium accumulation and DNA single-strand breakage elicited by tert-butylhydroperoxide: the source of the cation is a ryanodine-sensitive calcium store. Exp Cell Res 1999;249:65-9.
44. Jones ME. The genes for and regulation of the enzyme activities of two multifunctional proteins required for the de novo pathway for UMP biosynthesis in mammals. Mol Biol Biochem Biophys 1980;32:165-82.
45. Boutros J, Almasan A. Combining 2-deoxy-D-glucose with electron transport chain blockers: a double-edged sword. Cancer Biol Ther 2009;8:1237-8.